NO20013701D0 - HER-2/neu-fusjonsproteiner - Google Patents
HER-2/neu-fusjonsproteinerInfo
- Publication number
- NO20013701D0 NO20013701D0 NO20013701A NO20013701A NO20013701D0 NO 20013701 D0 NO20013701 D0 NO 20013701D0 NO 20013701 A NO20013701 A NO 20013701A NO 20013701 A NO20013701 A NO 20013701A NO 20013701 D0 NO20013701 D0 NO 20013701D0
- Authority
- NO
- Norway
- Prior art keywords
- fusion proteins
- neu
- neu fusion
- nucleic acid
- acid molecules
- Prior art date
Links
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 title abstract 8
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 title abstract 8
- 102000037865 fusion proteins Human genes 0.000 title abstract 5
- 108020001507 fusion proteins Proteins 0.000 title abstract 5
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 108700020796 Oncogene Proteins 0.000 abstract 1
- 108010059722 Viral Fusion Proteins Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000036210 malignancy Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
- 239000013603 viral vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11797699P | 1999-01-29 | 1999-01-29 | |
PCT/US2000/002164 WO2000044899A1 (en) | 1999-01-29 | 2000-01-28 | Her-2/neu fusion proteins |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20013701D0 true NO20013701D0 (no) | 2001-07-27 |
NO20013701L NO20013701L (no) | 2001-09-28 |
Family
ID=22375831
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20013701A NO20013701L (no) | 1999-01-29 | 2001-07-27 | HER-2/neu-fusjonsproteiner |
Country Status (20)
Country | Link |
---|---|
EP (1) | EP1147190B1 (no) |
JP (1) | JP5164300B2 (no) |
KR (1) | KR100766653B1 (no) |
CN (1) | CN1201004C (no) |
AT (1) | ATE474048T1 (no) |
AU (1) | AU780109B2 (no) |
BR (1) | BR0007840A (no) |
CA (1) | CA2361009C (no) |
CZ (1) | CZ20012587A3 (no) |
DE (1) | DE60044665D1 (no) |
ES (1) | ES2348708T3 (no) |
HK (1) | HK1044798A1 (no) |
HU (1) | HUP0105303A2 (no) |
IL (1) | IL144371A0 (no) |
MX (1) | MXPA01007721A (no) |
NO (1) | NO20013701L (no) |
NZ (1) | NZ513062A (no) |
TR (1) | TR200102191T2 (no) |
WO (1) | WO2000044899A1 (no) |
ZA (1) | ZA200106179B (no) |
Families Citing this family (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7198920B1 (en) | 1999-01-29 | 2007-04-03 | Corika Corporation | HER-2/neu fusion proteins |
JP2003510334A (ja) | 1999-09-30 | 2003-03-18 | コリクサ コーポレイション | 癌及び感染症の予防及び治療のためのストレスタンパク質組成物及び方法 |
US7378096B2 (en) | 1999-09-30 | 2008-05-27 | Health Research, Inc. | Stress protein compositions and methods for prevention and treatment of cancer and infectious disease |
WO2001048205A2 (en) * | 1999-12-29 | 2001-07-05 | Corixa Corporation | Murine neu sequences and methods of use therefor |
PT1272633E (pt) * | 2000-03-30 | 2011-06-27 | Dendreon Corp | Composições e métodos para imunoterapia baseada em células dendríticas |
US7229623B1 (en) | 2000-08-03 | 2007-06-12 | Corixa Corporation | Her-2/neu fusion proteins |
CN1537164A (zh) * | 2000-08-14 | 2004-10-13 | 治疗和诊断Her-2/neu相关恶性肿瘤的组合物和方法 | |
ES2295229T3 (es) * | 2000-10-18 | 2008-04-16 | Glaxosmithkline Biologicals S.A. | Vacunas contra canceres. |
EP2266603B1 (en) | 2000-10-18 | 2012-09-12 | GlaxoSmithKline Biologicals S.A. | Tumour vaccines |
GB0109297D0 (en) | 2001-04-12 | 2001-05-30 | Glaxosmithkline Biolog Sa | Vaccine |
NZ530315A (en) | 2001-07-10 | 2007-01-26 | Corixa Corp | Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres |
WO2004067716A2 (en) | 2003-01-24 | 2004-08-12 | Agensys, Inc. | Nucleic acids and corresponding proteins entitled 254p1d6b useful in treatment and detection of cancer |
EP1635766A4 (en) | 2003-06-06 | 2009-09-30 | Agennix Inc | LACTOFERRIN AS ADJUVANS IN CANCER VACCINES |
EA008827B1 (ru) | 2003-06-25 | 2007-08-31 | Фармекса А/С | Очистка вариантов her-2 |
MXPA05013389A (es) * | 2003-06-25 | 2006-03-17 | Pharmexa As | Purificacion de variantes her-2. |
JP4772674B2 (ja) * | 2003-07-21 | 2011-09-14 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | ヒト上皮成長因子2/neu抗原をコードする合成遺伝子およびその用途 |
GB0321615D0 (en) | 2003-09-15 | 2003-10-15 | Glaxo Group Ltd | Improvements in vaccination |
BR122018071808B8 (pt) | 2003-11-06 | 2020-06-30 | Seattle Genetics Inc | conjugado |
KR101200133B1 (ko) | 2004-06-01 | 2012-11-13 | 제넨테크, 인크. | 항체 약물 접합체 및 방법 |
CA2580141C (en) | 2004-09-23 | 2013-12-10 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
ITMI20041965A1 (it) * | 2004-10-15 | 2005-01-15 | Augusto Amici | "dna codificante forme tronche e chimeriche della proteina p185neu e suoi usi terapeutici" |
GB0427131D0 (en) * | 2004-12-10 | 2005-01-12 | Glaxosmithkline Biolog Sa | Novel combination |
TWI457133B (zh) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
AR061136A1 (es) | 2006-06-02 | 2008-08-06 | Glaxosmithkline Biolog Sa | Procedimiento |
CL2008001491A1 (es) | 2007-05-24 | 2008-11-28 | Glaxosmithkline Biolog Sa | Composicion liofilizada que comprende uno o mas antigenos y un agonista del receptor de tipo toll 9 (tlr9); y procedimiento de preparacion. |
IN2012DN03025A (no) | 2009-09-09 | 2015-07-31 | Ct Se Llc | |
GB0917457D0 (en) | 2009-10-06 | 2009-11-18 | Glaxosmithkline Biolog Sa | Method |
BR112012026213B1 (pt) | 2010-04-15 | 2021-12-28 | Medimmune Limited | Compostos de pirrolobenzodiazepinas, conjugado das mesmas, composição farmacêutica compreendendo o conjugado e uso do mesmo para o tratamento de uma doença proliferativa |
CA2799540A1 (en) | 2010-06-08 | 2011-12-15 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
JP5889912B2 (ja) | 2010-11-17 | 2016-03-22 | ジェネンテック, インコーポレイテッド | アラニニルメイタンシノール抗体コンジュゲート |
CA2833212C (en) | 2011-05-12 | 2020-06-09 | Genentech, Inc. | Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature peptides |
KR101877598B1 (ko) | 2011-10-14 | 2018-07-11 | 메디뮨 리미티드 | 피롤로벤조디아제핀 및 그의 컨주게이트 |
WO2013130093A1 (en) | 2012-03-02 | 2013-09-06 | Genentech, Inc. | Biomarkers for treatment with anti-tubulin chemotherapeutic compounds |
PT2839860T (pt) | 2012-10-12 | 2019-07-29 | Medimmune Ltd | Pirrolobenzodiazepinas e conjugados das mesmas |
ES2660029T3 (es) | 2012-10-12 | 2018-03-20 | Medimmune Limited | Conjugados de anticuerpo-pirrolobenzodiazepinas |
HUE035694T2 (en) | 2012-10-12 | 2018-05-28 | Adc Therapeutics Sa | Pirrolobenzodiazepine anti-CD22 antibody conjugates |
ES2703151T3 (es) | 2012-10-12 | 2019-03-07 | Adc Therapeutics Sa | Conjugados de anticuerpos de pirrolobenzodiazepinas |
SI2906296T1 (en) | 2012-10-12 | 2018-06-29 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
EP2906250B1 (en) | 2012-10-12 | 2018-05-30 | ADC Therapeutics SA | Pyrrolobenzodiazepine-anti-psma antibody conjugates |
NZ707486A (en) | 2012-10-12 | 2018-09-28 | Adc Therapeutics Sa | Pyrrolobenzodiazepine - anti-psma antibody conjugates |
CN105246894A (zh) | 2012-12-21 | 2016-01-13 | 斯皮罗根有限公司 | 用于治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物 |
EA031585B1 (ru) | 2012-12-21 | 2019-01-31 | Медимьюн Лимитед | Пирролобензодиазепины и их конъюгаты |
CN105142674B (zh) | 2013-03-13 | 2018-11-13 | 麦迪穆有限责任公司 | 吡咯并苯并二氮杂卓和其结合物 |
NZ710745A (en) | 2013-03-13 | 2019-03-29 | Genentech Inc | Pyrrolobenzodiazepines and conjugates thereof |
JP6444902B2 (ja) | 2013-03-13 | 2018-12-26 | メドイミューン・リミテッドMedImmune Limited | ピロロベンゾジアゼピン及びその結合体 |
AU2014307080B2 (en) | 2013-08-12 | 2018-06-07 | Genentech, Inc. | 1-(chloromethyl)-2,3-dihydro-1H-benzo(E)indole dimer antibody-drug conjugate compounds, and methods of use and treatment |
EP3054985B1 (en) | 2013-10-11 | 2018-12-26 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
EP3054983B1 (en) | 2013-10-11 | 2019-03-20 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
WO2015052535A1 (en) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
GB201317982D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
JP6425327B2 (ja) * | 2013-12-12 | 2018-11-21 | 国立大学法人東京農工大学 | タンパク質−磁性粒子複合体及びその製造方法 |
CA2928952A1 (en) | 2013-12-16 | 2015-06-25 | Genentech, Inc. | Peptidomimetic compounds and antibody-drug conjugates thereof |
JP6895254B2 (ja) | 2013-12-16 | 2021-06-30 | ジェネンテック, インコーポレイテッド | ペプチド模倣化合物及びその抗体−薬物コンジュゲート |
CA2929565A1 (en) | 2013-12-16 | 2015-06-25 | Genentech, Inc. | 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment |
US10188746B2 (en) | 2014-09-10 | 2019-01-29 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
EP3191134B1 (en) | 2014-09-12 | 2019-11-20 | Genentech, Inc. | Anthracycline disulfide intermediates, antibody-drug conjugates and methods |
US10077318B2 (en) | 2014-09-12 | 2018-09-18 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
GB201416112D0 (en) | 2014-09-12 | 2014-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
MA40575A (fr) | 2014-09-17 | 2016-03-24 | Genentech Inc | Pyrrolobenzodiazépines et conjugués à base de disulfure d'anticorps associés |
AU2015352545B2 (en) | 2014-11-25 | 2020-10-15 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
WO2016090050A1 (en) | 2014-12-03 | 2016-06-09 | Genentech, Inc. | Quaternary amine compounds and antibody-drug conjugates thereof |
GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
GB201506402D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
MA43345A (fr) | 2015-10-02 | 2018-08-08 | Hoffmann La Roche | Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation |
MA43354A (fr) | 2015-10-16 | 2018-08-22 | Genentech Inc | Conjugués médicamenteux à pont disulfure encombré |
MA45326A (fr) | 2015-10-20 | 2018-08-29 | Genentech Inc | Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation |
GB201601431D0 (en) | 2016-01-26 | 2016-03-09 | Medimmune Ltd | Pyrrolobenzodiazepines |
GB201602359D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
GB201602356D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
JP6943872B2 (ja) | 2016-03-25 | 2021-10-06 | ジェネンテック, インコーポレイテッド | 多重全抗体及び抗体複合体化薬物定量化アッセイ |
GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
JP2019522633A (ja) | 2016-05-20 | 2019-08-15 | ジェネンテック, インコーポレイテッド | Protac抗体コンジュゲート及び使用方法 |
US20170370906A1 (en) | 2016-05-27 | 2017-12-28 | Genentech, Inc. | Bioanalytical analysis of site-specific antibody drug conjugates |
EP3464280B1 (en) | 2016-06-06 | 2021-10-06 | F. Hoffmann-La Roche AG | Silvestrol antibody-drug conjugates and methods of use |
EP3496763A1 (en) | 2016-08-11 | 2019-06-19 | Genentech, Inc. | Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof |
EP3522933B1 (en) | 2016-10-05 | 2021-12-15 | F. Hoffmann-La Roche AG | Methods for preparing antibody drug conjugates |
GB201617466D0 (en) | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
RS61795B1 (sr) | 2017-02-08 | 2021-06-30 | Adc Therapeutics Sa | Konjugati pirolobenzodiazepin antitela |
WO2018192944A1 (en) | 2017-04-18 | 2018-10-25 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
EP3612234B1 (en) | 2017-04-20 | 2024-03-13 | ADC Therapeutics SA | Combination therapy with an anti-axl antibody-drug conjugate |
MX2019015042A (es) | 2017-06-14 | 2020-08-06 | Adc Therapeutics Sa | Regimen de dosificacion. |
AU2018316532B2 (en) | 2017-08-18 | 2022-11-24 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
IL273387B2 (en) | 2017-09-20 | 2023-10-01 | Ph Pharma Co Ltd | Thylanstatin analogs |
GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
GB201814281D0 (en) | 2018-09-03 | 2018-10-17 | Femtogenix Ltd | Cytotoxic agents |
JP2022505450A (ja) | 2018-10-24 | 2022-01-14 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | コンジュゲート化された化学的分解誘導物質および使用方法 |
WO2020123275A1 (en) | 2018-12-10 | 2020-06-18 | Genentech, Inc. | Photocrosslinking peptides for site specific conjugation to fc-containing proteins |
GB201901197D0 (en) | 2019-01-29 | 2019-03-20 | Femtogenix Ltd | G-A Crosslinking cytotoxic agents |
KR20230037560A (ko) * | 2020-07-14 | 2023-03-16 | 에프. 호프만-라 로슈 아게 | 고정 용량 조합에 대한 분석 |
GB2597532A (en) | 2020-07-28 | 2022-02-02 | Femtogenix Ltd | Cytotoxic compounds |
KR102584276B1 (ko) * | 2023-03-30 | 2023-10-10 | 주식회사 애스톤사이언스 | Her2 백신, 및 면역관문 억제제의 조합 요법 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990014357A1 (en) * | 1989-05-19 | 1990-11-29 | Genentech, Inc. | Her2 extracellular domain |
US5801005A (en) * | 1993-03-17 | 1998-09-01 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated |
JPH0914357A (ja) * | 1995-06-27 | 1997-01-14 | Honda Motor Co Ltd | 伝動ベルト用ブロック |
-
2000
- 2000-01-28 CN CNB008057524A patent/CN1201004C/zh not_active Expired - Fee Related
- 2000-01-28 TR TR2001/02191T patent/TR200102191T2/xx unknown
- 2000-01-28 AT AT00905800T patent/ATE474048T1/de not_active IP Right Cessation
- 2000-01-28 CA CA2361009A patent/CA2361009C/en not_active Expired - Fee Related
- 2000-01-28 IL IL14437100A patent/IL144371A0/xx unknown
- 2000-01-28 AU AU27426/00A patent/AU780109B2/en not_active Ceased
- 2000-01-28 HU HU0105303A patent/HUP0105303A2/hu unknown
- 2000-01-28 EP EP00905800A patent/EP1147190B1/en not_active Expired - Lifetime
- 2000-01-28 MX MXPA01007721A patent/MXPA01007721A/es not_active Application Discontinuation
- 2000-01-28 BR BR0007840-9A patent/BR0007840A/pt not_active IP Right Cessation
- 2000-01-28 JP JP2000596141A patent/JP5164300B2/ja not_active Expired - Fee Related
- 2000-01-28 WO PCT/US2000/002164 patent/WO2000044899A1/en not_active Application Discontinuation
- 2000-01-28 ES ES00905800T patent/ES2348708T3/es not_active Expired - Lifetime
- 2000-01-28 CZ CZ20012587A patent/CZ20012587A3/cs unknown
- 2000-01-28 NZ NZ513062A patent/NZ513062A/en unknown
- 2000-01-28 DE DE60044665T patent/DE60044665D1/de not_active Expired - Lifetime
- 2000-01-28 KR KR1020017009563A patent/KR100766653B1/ko not_active IP Right Cessation
-
2001
- 2001-07-26 ZA ZA200106179A patent/ZA200106179B/en unknown
- 2001-07-27 NO NO20013701A patent/NO20013701L/no unknown
-
2002
- 2002-08-26 HK HK02106267A patent/HK1044798A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
ATE474048T1 (de) | 2010-07-15 |
ZA200106179B (en) | 2002-12-24 |
AU780109B2 (en) | 2005-03-03 |
AU2742600A (en) | 2000-08-18 |
CA2361009A1 (en) | 2000-08-03 |
NZ513062A (en) | 2003-10-31 |
EP1147190A1 (en) | 2001-10-24 |
BR0007840A (pt) | 2002-01-22 |
JP5164300B2 (ja) | 2013-03-21 |
KR100766653B1 (ko) | 2007-10-15 |
KR20010101865A (ko) | 2001-11-15 |
CZ20012587A3 (cs) | 2002-05-15 |
CN1345374A (zh) | 2002-04-17 |
WO2000044899A1 (en) | 2000-08-03 |
IL144371A0 (en) | 2002-05-23 |
CA2361009C (en) | 2012-10-23 |
HUP0105303A2 (en) | 2002-05-29 |
ES2348708T3 (es) | 2010-12-13 |
HK1044798A1 (en) | 2002-11-01 |
JP2002535004A (ja) | 2002-10-22 |
NO20013701L (no) | 2001-09-28 |
TR200102191T2 (tr) | 2001-12-21 |
EP1147190B1 (en) | 2010-07-14 |
DE60044665D1 (de) | 2010-08-26 |
MXPA01007721A (es) | 2003-07-14 |
CN1201004C (zh) | 2005-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20013701D0 (no) | HER-2/neu-fusjonsproteiner | |
WO2002012341A3 (en) | Her-2/neu fusion proteins | |
HUP0302532A2 (hu) | Petefészekrák terápiájában és diagnosztizálásában alkalmazható készítmények és eljárások | |
FI932678A0 (fi) | Pao alfavirus baserande DNA expressionssystem | |
BR0113921A (pt) | ácidos nucléicos e polipeptìdeos receptores | |
DE69634912D1 (de) | Intrazellulare domäne des her-2/neu proteins, für die prevention oder behandlung von bösartigen tumoren | |
SG153874A1 (en) | Neutralizing epitope-based growth enhancing vaccine | |
BRPI0511118A (pt) | polipeptìdeos de haemophilus influenzae não transcritos | |
CY1114265T1 (el) | Πρωτεϊνη συντηξης αλβουμινης | |
EP1408986A4 (en) | PROTEOMIMETIC COMPOUNDS AND CORRESPONDING METHODS | |
BR9608615A (pt) | Vacinas de vírus sincicial respiratório de ácido nucléico | |
CY1107351T1 (el) | Καινοφανης μεταλλαγμενη μορφη απιμινασης αργινινης | |
DE19580890D2 (de) | Lebendvakzine zur Behandlung von Tumorerkrankungen | |
DK1082423T3 (da) | Cyclin E2-gener og -proteiner | |
DK1290160T3 (da) | Humane Pellino-polypeptider | |
WO2001040313A3 (en) | Feline immunoregulatory proteins, nucleic acid molecules, and uses thereof | |
AU6987696A (en) | The use of the wap of mmtv regulatory sequences for targeted expression of linked heterologous genes in human mammary cells, including human mammary carcinoma cells | |
ATE381351T1 (de) | Anwendung des herpes simplex virus glykoproteins- d zur unterdrückung von immunantworten | |
DE60334008D1 (de) | Reduzierter slam abhängiger zell eintritt | |
WO2001004143A3 (en) | Prostase vaccine | |
BR0207033A (pt) | variantes de amina oxidase ap1 | |
WO2003016343A3 (en) | USE OF αCP1, αCP2, AND HUR FOR MODULATING GENE EXPRESSION AND INDUCING ANGIOGENESIS | |
BR0110791A (pt) | Composição, métodos para induzir uma resposta imune em um indivìduo contra um imunogene, para modular o sistema imune de um indivìduo e para imunizar um indivìduo contra um patógeno, vacina recombinante, e patógeno atenuado vivo | |
NO20005321L (no) | Vertskodet protein uttrykt i Mareks sykdoms (MDV) infiserte celler og antistoffer til dette | |
DE69733320D1 (de) | Differenzierungsfaktor der hypophyse und methoden zu seiner verwendung. |